PhilipDLemingMD

Oncology • Cincinnati, OH

Hematologic Oncology, Melanoma

Consultant Cincinnati Cancer Advisors Independent Oncology Second Opinion Program

Join to view full profile

Dr. Leming is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Leming's full profile

Already have an account?

Office
4746 Montgomery Rd.
Ste 201
Cincinnati, OH 45212
Phone+1 513-731-2273

Fax+1 513-731-2274
Is this information wrong?

Education & Training

NIH Clinical CenterResidency, CANCER RESEARCH - CLINICAL ASSOCIATE, 1981 - 1983
University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 1980 - 1981
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1975 - 1979
University of Louisville School of MedicineClass of 1975

Certifications & Licensure

FL State Medical License 2022 - 2025
KY State Medical License 1997 - 2025
OH State Medical License 1977 - 2024
MD State Medical License 1981 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top MD Consumers Checkbook

Clinical Trials

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN) Start of enrollment: 2011 Aug 01
Suspended
Not Applicable
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01
Terminated
Phase 4
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2013 May 01
Terminated
Phase 4
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
RTA 408 Capsules in Patients With Melanoma - REVEAL Start of enrollment: 2014 Oct 31
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

5 citations
Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing.
Mohammed Kashani-Sabet, Sancy A Leachman, Jennifer A Stein, Jack L Arbiser, Elizabeth G Berry, Julide T Celebi, Clara Curiel-Lewandrowski, Laura K Ferris, Jane M Grant...> ;JAMA Dermatology. 2023 May 1
55 citations
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit
Douglas Grossman, Nwanneka Okwundu, Edmund K. Bartlett, Michael A. Marchetti, Megan Othus, Daniel G. Coit, Rebecca I. Hartman, Sancy A. Leachman, Elizabeth G. Berry, L...> ;JAMA Dermatology. 2020 Sep 1
345 citations
Five-Year Survival and Correlates among Patients with Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated with Nivolumab
, , , , , , , , , , , , , , , , , , > ;JAMA Oncology. 2019 Oct 1
471 citations
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
Scott N. Gettinger, Leora Horn, David M. Jackman, David R. Spigel, Scott J. Antonia, Matthew D. Hellmann, John D. Powderly, Rebecca S. Heist, Lecia V. Sequist, David S...> ;Journal of Clinical Oncology. 2018 Mar 23
79 citations
Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.
Mariah M. Johnson, Sancy A. Leachman, Lisa G. Aspinwall, Lee D. Cranmer, Clara Curiel-Lewandrowski, Vernon K. Sondak, Clara E. Stemwedel, Susan M. Swetter, John T. Vet...> ;Melanoma Management. 2017 Mar 1
961 citations
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell...
Scott N. Gettinger, Leora Horn, Leena Gandhi, David R. Spigel, Scott J. Antonia, Naiyer A. Rizvi, John D. Powderly, Rebecca S. Heist, Richard D. Carvajal, David M. Jac...> ;Journal of Clinical Oncology. 2015 Apr 20
278 citations
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.
F. Stephen Hodi, Sandra J. Lee, David F. McDermott, Uma N. M. Rao, Lisa H. Butterfield, Ahmad A. Tarhini, Philip D. Leming, Igor Puzanov, Donghoon Shin, John M. Kirkwood> ;JAMA. 2014 Nov 5
1862 citations
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian, Mario Sznol, David F. McDermott, Harriet M. Kluger, Richard D. Carvajal, William H. Sharfman, Julie R. Brahmer, Donald P. Lawrence, Michael B. Atk...> ;Journal of Clinical Oncology. 2014 Apr 1
81 citations
A Randomized Phase II Trial of Multiepitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602)
Craig L. Slingluff, Sandra J. Lee, Fengmin Zhao, Kimberly A. Chianese-Bullock, Walter C. Olson, Lisa H. Butterfield, Theresa L. Whiteside, Philip D. Leming, John M. Ki...> ;Clinical Cancer Research. 2013 May 7
154 citations
Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma
Keith T. Flaherty, Sandra J. Lee, Fengmin Zhao, Lynn M. Schuchter, Lawrence E. Flaherty, Richard F. Kefford, Michael B. Atkins, Philip D. Leming, John M. Kirkwood> ;Journal of Clinical Oncology. 2013 Jan 20
9185 citations
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott N. Gettinger, David Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, ...> ;The New England Journal of Medicine. 2012 Jun 27
29 citations
Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer.
Elizabeth Poplin, Patricia LoRusso, Jacob J. Lokich, John J. Gullo, Philip D. Leming, Joseph J. Schulz, Stephen R. Veach, William McCulloch, Laurence H. Baker, Philip ...> ;Cancer Chemotherapy and Pharmacology. 1994 Jan 1
1 citations
Nonspecific corticosteroid therapy in patients receiving intra-arterial chemotherapy for hepatic metastases of colorectal origin.
Lesley W. Janis, Philip D. Leming, Wilfried Leder> ;Cancer Investigation. 1988 Jan 1
23 citations
Atypical herpes simplex (HSV) infection in a patient with Hodgkin's disease.
Philip D. Leming, Susan E. Martin, Leonard A. Zwelling> ;Cancer. 1984 Dec 15
Join now to see all

Journal Articles

Prognostic Gene Expression Profiling in Cutaneous Melanoma
Douglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Joanne..., JAMA Dermatology